Hidehito HORINOUCHI· @HHorinouchi · X·· 3 小时前评分70
正文 · 机器翻译
🆙#ESMO26 口头报告论文 II：#LCSM 转移瘤
🔥Dalmelitinib 联合 Aumolertinib 对比含铂化疗治疗 EGFR TKI 治疗后出现 MET 扩增的晚期 NSCLC 患者：一项随机、3 期研究
🎙️李子明医生
🔢2615O
🎯MET 主要终点
🎯IRC-PFS：6.2 vs 4.4 个月（HR 0.601，p<0.001；n=314）
🎯ORR 59.6% vs 38.6%
🎯OS HR 0.840（数据尚不成熟，46.8% 交叉）
🎯≥3 级 TEAEs 50.0% vs 51.0%
☑️NCT06110663
🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/283
@OncoAlert @Larvol @myESMO @IASLC @EGFRResisters
45 浏览 · 0 赞 · 2 转发 · 0 回复
会议摘要
dalmelitinib + aumolertinib
https://esmocongress.esmo.orgNCT06110663NCT06110663按 - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy 对上
- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.org🆙#ESMO26 Proffered Paper II: #LCSM Mets 🔥Dalmelitinib Plus Aumolertinib Versus Platinum-Based Chemotherapy in Advanced NSCLC Patients With MET Amplification Post EGFR TKI: A Randomized, Phase 3 Study 🎙️Dr. Ziming Li 🔢2615O 🎯Met Primary Endpoint: IRC-PFS 6.2 vs 4.4mo (HR 0.601, p<0.001; n=314); ORR 59.6% vs 38.6%; OS HR 0.840 (Immature, 46.8% Crossover); Grade≥3 TEAEs 50.0% vs 51.0% ☑️NCT06110663 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/283 @OncoAlert @Larvol @myESMO @IASLC @EGFRResisters在 X 查看被引用的帖子
来源：Hidehito HORINOUCHI · x.com